E
Enalare Therapeutics
Developing novel therapies for patients suffering from acute respiratory conditions
About Enalare Therapeutics
Enalare Therapeutics is a biopharmaceutical startup that focuses on developing novel compounds to address acute respiratory depression, a serious health issue that can lead to overdose deaths and complications in preterm infants and high-risk surgical patients. The company operates in the healthcare and pharmaceutical market, serving a broad range of clients including hospitals, healthcare providers, and potentially, patients directly.
The business model of Enalare Therapeutics is centered around the research, development, and commercialization of innovative pharmaceutical products. The company's revenue generation strategy is likely to involve the sale of these developed drugs to healthcare institutions or through prescription to patients.
The team at Enalare Therapeutics comprises experienced professionals from top-tier biopharma companies, scientific advisors of global repute, and a skilled workforce. They have a proven track record of developing and launching innovative products and creating significant shareholder value.
In summary, Enalare Therapeutics is a promising startup in the biopharmaceutical industry, with a focus on addressing acute respiratory depression through the development of novel compounds. Its experienced team and innovative approach position it well for future growth and success in the healthcare market.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Sep 2024 | $0 | — | US Department of Health and Human Services | ↗ |
| GRANT✓Other financing | Feb 2023 | $30K | — | New Jersey Economic Development Authority | ↗ |
Growth signals
Latest recorded traffic for Enalare Therapeutics is 3K monthly website visits, up 1900% over the last three months. Enalare Therapeutics's team declined 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Enalare Therapeutics in the Mantua Township ecosystem
The Enalare Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
New Jersey Economic Development Authority
US Department of Health and Human Services
Series A1 investor entered at this stage
Eagle Pharmaceuticals
Other known investors2 additional known investors
DRIVe - Division of Research, Innovation, and Ventures
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Enalare Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Enalare Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










